CYBIN INC. Annual Report - How They Did This Year

I’ve put together this plain-English guide to help you understand Cybin Inc.’s performance over the past year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment strategy.

1. What does this company do?

Cybin Inc. (doing business as Helus Pharma) is a clinical-stage drug company. They research and develop psychedelic-based treatments for mental health. They are currently in the testing phase, working to get their proprietary drugs—specifically HLP003 and HLP004—approved by regulators like the FDA. They do not have any products for sale yet.

2. Financial performance

As of their fiscal year ending March 31, 2026, the company has not generated any profit from product sales. Their financial statements show significant losses, which are expected for a company in the research and development phase. These costs are driven by clinical trials, patent management, and corporate operations.

Currency Change: Starting April 1, 2025, the company switched its reporting currency from Canadian dollars to U.S. dollars. This aligns better with their spending and makes it easier for international investors to compare results.

3. Key figures for investors

• Share Consolidation: On September 19, 2024, the company performed a 1-for-38 reverse stock split. All historical figures have been adjusted to reflect this change.
• Status: The company qualifies as an "Emerging Growth Company," which grants them exemptions from certain financial reporting rules that larger public companies must follow.
• Exchange: Shares trade on the Nasdaq, subjecting the company to U.S. securities regulations alongside their Canadian reporting duties.

4. Financial health and "Cash Burn"

Cybin is in a "cash burn" phase. Because they have no product revenue, they fund their operations by selling more shares. Investors should monitor their "cash runway"—the amount of time their current cash will last before they need to raise more capital. Future funding will likely involve issuing more shares, which can dilute the ownership percentage of existing shareholders.

5. Governance and Oversight

The company operates as a "foreign private issuer" on the Nasdaq, following Canadian corporate governance standards. They maintain an independent Audit Committee to oversee financial integrity and enforce a formal "Code of Business Conduct" for all staff.

6. Key risks that could hurt the stock price

• Regulatory Hurdles: The company’s value depends entirely on the success of HLP003 and HLP004. Because these are controlled substances, they face strict scrutiny. If the FDA or other regulators do not approve these drugs, these assets could lose their value.
• Clinical Trial Uncertainty: Drug development is inherently unpredictable. If clinical trials are delayed, face safety issues, or fail to show that the drugs work as intended, the stock price could drop significantly.
• No Guaranteed Benefits: Regulators have not yet evaluated these drugs for safety or effectiveness, and there is no guarantee they will ever reach the market.

7. Competitive positioning

Helus Pharma aims to lead in next-generation mental health treatments. To manage risks in this highly regulated sector, they employ legal experts in the U.S., Canada, UK, and EU to ensure they follow international drug laws and protect their intellectual property.

8. Future outlook

The company’s roadmap focuses on advancing clinical trials, growing their patent portfolio, and navigating regulatory pathways. Management confirmed that their internal controls over financial reporting were effective as of March 31, 2026.

Investor Takeaway: Cybin is a high-risk, high-reward play. Because they have no revenue and rely on share offerings to fund their research, your investment is essentially a bet on the success of their clinical trials and their ability to navigate the FDA approval process. Keep a close eye on their cash balance and any updates regarding their drug pipeline.